Vimarsana
Biggest News Aggregation in the World

Page 49 - Confidence Interval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Confidence Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Confidence Interval Today - Breaking & Trending Today

Heart transplantation after circulatory death noninferior to standard-care transplantation - Vimarsana News

Heart transplantation after circulatory death noninferior to standard-care transplantation

1. In this randomized controlled trial, compared to heart transplantation from a brain death donor, recipients of hearts from donors following circulatory death had similar six-month survival. 2. There were no significant differences in the number of serious adverse events 30 days post-operatively between standard-care and post-circulatory death transplantation. Evidence Rating Level: 1 (Excellent) Study

Craniotomy and decompressive craniectomy comparable in managing acute subdural hematoma - Vimarsana News

Craniotomy and decompressive craniectomy comparable in managing acute subdural hematoma

1. In this randomized controlled trial, craniotomy and decompressive craniectomy resulted in similar disability and quality-of-life outcomes for patients following traumatic acute subdural hematoma. 2. Additional surgery was performed more frequently after craniotomy, but craniectomy was associated with more wound complications. Evidence Rating Level: 1 (Excellent) Study Rundown: Post-traumatic subdural hematoma is associated with high

SURMOUNT-2: Tirzepatide Demonstrates Body Weight-Lowering Effects in T2D - Vimarsana News

SURMOUNT-2: Tirzepatide Demonstrates Body Weight-Lowering Effects in T2D

Data from SURMOUNT-2 presented at ADA 2023 build on results from the SURMOUNT-1 trial, with results detailing the weight loss achieved with tirzepatide in people with type 2 diabetes and overweight or obesity.

Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) - Vimarsana News

Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2023--

Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) - Vimarsana News

Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2023--